Hans LennernÃ¤s

List of Publications by Year
in descending order

159 papers	15,207 citations	34100 52 h-index	18647 119 g-index
189 all docs	189 docs citations	189 times ranked	10994 citing authors

#	Article	IF	Citations
1	A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 1995, 12, 413-420.	3.5	4,287
2	Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Molecular Pharmaceutics, 2004, 1, 85-96.	4.6	691
3	Clinical Pharmacokinetics of Atorvastatin. Clinical Pharmacokinetics, 2003, 42, 1141-1160.	3.5	482
4	Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors. Clinical Pharmacokinetics, 1997, 32, 403-425.	3.5	447
5	Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis Approach. Journal of Medicinal Chemistry, 1998, 41, 4939-4949.	6.4	420
6	Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical Research, 1996, 13, 1336-1342.	3.5	385
7	Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharmaceutical Research, 2002, 19, 1400-1416.	3.5	362
8	Characterization of fluids from the stomach and proximal jejunum in men and women. Pharmaceutical Research, 1997, 14, 497-502.	3.5	345
9	Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model. Pharmaceutical Research, 2006, 23, 1675-1686.	3.5	344
10	The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids. Pharmaceutical Research, 2005, 22, 2141-2151.	3.5	244
11	In vivo methods for drug absorption â€“ Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151.	4.0	226
12	Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets. Clinical Neuropharmacology, 2003, 26, 156-163.	0.7	206
13	ABSORPTION/METABOLISM OF SULFORAPHANE AND QUERCETIN, AND REGULATION OF PHASE II ENZYMES, IN HUMAN JEJUNUM IN VIVO. Drug Metabolism and Disposition, 2003, 31, 805-813.	3.3	199
14	Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharmaceutical Research, 1992, 09, 1243-1251.	3.5	191
15	Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models. Journal of Pharmacy and Pharmacology, 2011, 49, 627-638.	2.4	172
16	The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extensionâ€. Journal of Pharmacy and Pharmacology, 2010, 57, 273-285.	2.4	169
17	Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. European Journal of Endocrinology, 2009, 161, 119-130.	3.7	151
18	In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim. European Journal of Pharmaceutical Sciences, 2013, 49, 679-698.	4.0	141

#	Article	IF	Citations
19	Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches. Pharmaceutics, 2019, 11, 411.	4.5	140
20	SPR Biosensor Studies of the Direct Interaction between 27 Drugs and a Liposome Surface:Â Correlation with Fraction Absorbed in Humans. Journal of Medicinal Chemistry, 2000, 43, 2083-2086.	6.4	133
21	Pulmonary Absorption Rate and Bioavailability of Drugs in Vivo in Rats: Structureâ€“Absorption Relationships and Physicochemical Profiling of Inhaled Drugs. Journal of Pharmaceutical Sciences, 2003, 92, 1216-1233.	3.3	130
22	Animal data: The contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivoâ˜†. Advanced Drug Delivery Reviews, 2007, 59, 1103-1120.	13.7	128
23	The Use of BDDCS in Classifying the Permeability of Marketed Drugs. Pharmaceutical Research, 2008, 25, 483-488.	3.5	124
24	St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism*1. Clinical Pharmacology and Therapeutics, 2004, 75, 298-309.	4.7	118
25	Transport Characteristics of Fexofenadine in the Caco-2 Cell Model. Pharmaceutical Research, 2004, 21, 1398-1404.	3.5	116
26	Toward an Increased Understanding of the Barriers to Colonic Drug Absorption in Humans: Implications for Early Controlled Release Candidate Assessment. Molecular Pharmaceutics, 2009, 6, 60-73.	4.6	114
27	Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake Are Both Important Mechanisms of Membrane Permeation in Drug Disposition. Molecular Pharmaceutics, 2014, 11, 1727-1738.	4.6	106
28	Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man. Pharmaceutical Research, 1995, 12, 426-432.	3.5	97
29	Jejunal absorption and metabolism of R/S-verapamil in humans. Pharmaceutical Research, 1998, 15, 856-862.	3.5	95
30	Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?. Pharmaceutical Research, 1995, 12, 1573-1582.	3.5	94
31	High-Permeability Criterion for BCS Classification: Segmental/pH Dependent Permeability Considerations. Molecular Pharmaceutics, 2010, 7, 1827-1834.	4.6	94
32	Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. European Journal of Pharmaceutical Sciences, 1995, 3, 247-253.	4.0	92
33	Drug Absorption from the Isolated Perfused Rat Lungâ€“Correlations with Drug Physicochemical Properties and Epithelial Permeability. Journal of Drug Targeting, 2003, 11, 61-74.	4.4	91
34	Modeling Gastrointestinal Drug Absorption Requires More In Vivo Biopharmaceutical Data: Experience from In Vivo Dissolution and Permeability Studies in Humans. Current Drug Metabolism, 2007, 8, 645-657.	1.2	84
35	Regional Intestinal Permeability in Rats of Compounds with Different Physicochemical Properties and Transport Mechanisms. Journal of Pharmacy and Pharmacology, 2011, 49, 687-690.	2.4	84
36	Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods. Journal of Pharmaceutical Sciences, 2015, 104, 2702-2726.	3.3	83

#	Article	IF	Citations
37	Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine,. Clinical Pharmacology and Therapeutics, 2003, 74, 423-436.	4.7	81
38	The BCS, BDDCS, and Regulatory Guidances. Pharmaceutical Research, 2011, 28, 1774-1778.	3.5	77
39	Regional intestinal drug permeation: Biopharmaceutics and drug development. European Journal of Pharmaceutical Sciences, 2014, 57, 333-341.	4.0	77
40	Jejunal permeability and hepatic extraction of fluvastatin in humans. Clinical Pharmacology and Therapeutics, 1996, 60, 493-503.	4.7	76
41	The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. British Journal of Clinical Pharmacology, 1999, 48, 180-189.	2.4	74
42	Dissolution of hydrocortisone in human and simulated intestinal fluids. Pharmaceutical Research, 2000, 17, 183-189.	3.5	74
43	The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship. Molecular Pharmaceutics, 2012, 9, 1847-1851.	4.6	74
44	Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. European Journal of Pharmaceutical Sciences, 2004, 21, 553-560.	4.0	71
45	The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. British Journal of Clinical Pharmacology, 2003, 55, 182-190.	2.4	70
46	Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development. Molecular Pharmaceutics, 2014, 11, 12-23.	4.6	69
47	A Clinical Single-Pass Perfusion Investigation of the Dynamic in Vivo Secretory Response to a Dietary Meal in Human Proximal Small Intestine. Pharmaceutical Research, 2006, 23, 742-751.	3.5	66
48	Chemotherapy and Antiangiogenesis. Acta OncolÃ³gica, 2003, 42, 294-303.	1.8	60
49	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. Journal of Pharmaceutical Sciences, 2014, 103, 3377-3397.	3.3	60
50	Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors. International Journal of Pharmaceutics, 2007, 341, 134-142.	5.2	58
51	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. European Journal of Pharmaceutical Sciences, 2017, 96, 610-625.	4.0	58
52	Regional Intestinal Permeability of Three Model Drugs in Human. Molecular Pharmaceutics, 2016, 13, 3013-3021.	4.6	57
53	Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies. Frontiers in Pharmacology, 2021, 12, 681417.	3.5	57
54	Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. European Journal of Pharmaceutical Sciences, 2006, 29, 205-214.	4.0	55

#	Article	IF	Citations
55	Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharmaceutical Research, 2001, 18, 742-744.	3.5	54
56	Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharmaceutical Research, 1997, 14, 1127-1132.	3.5	53
57	The Critical Role of Passive Permeability in Designing Successful Drugs. ChemMedChem, 2020, 15, 1862-1874.	3.2	53
58	Human in Vivo Regional Intestinal Permeability: Quantitation Using Site-Specific Drug Absorption Data. Molecular Pharmaceutics, 2015, 12, 2026-2039.	4.6	52
59	Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. European Journal of Pharmaceutical Sciences, 2011, 43, 89-98.	4.0	49
60	In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations. Molecular Pharmaceutics, 2017, 14, 4233-4242.	4.6	49
61	Presentation of a Structurally Diverse and Commercially Available Drug Data Set for Correlation and Benchmarking Studies. Journal of Medicinal Chemistry, 2006, 49, 6660-6671.	6.4	48
62	Simultaneous assessment of lipid classes and bile acids in human intestinal fluid by solid-phase extraction and HPLC methods. Journal of Lipid Research, 2007, 48, 242-251.	4.2	47
63	Ethanolâ^'Drug Absorption Interaction: Potential for a Significant Effect on the Plasma Pharmacokinetics of Ethanol Vulnerable Formulations. Molecular Pharmaceutics, 2009, 6, 1429-1440.	4.6	47
64	Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterology and Motility, 2019, 31, e13617.	3.0	46
65	The Lack of Effect of Induced Net Fluid Absorption on thein vivoPermeability of Terbutaline in the Human Jejunum. Journal of Drug Targeting, 1995, 3, 191-200.	4.4	45
66	The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. Pharmaceutical Research, 1994, 11, 1540-1544.	3.5	43
67	In Vivo Dog Intestinal Precipitation of Mebendazole: A Basic BCS Class II Drug. Molecular Pharmaceutics, 2012, 9, 2903-2911.	4.6	42
68	Miniaturized Nebulization Catheters: A New Approach for Delivery of Defined Aerosol Doses to the Rat Lung. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 283-296.	1.2	41
69	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. European Journal of Pharmaceutical Sciences, 2017, 96, 626-642.	4.0	41
70	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded â€˜21st Century BA/BEâ€™ project. International Journal of Pharmaceutics, 2018, 548, 120-127.	5.2	41
71	Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers, 2019, 11, 1024.	3.7	41
72	A Residence-Time Distribution Analysis of the Hydrodynamics within the Intestine in Man during a Regional Single-pass Perfusion with Loc-I-Gut: In-vivo Permeability Estimation. Journal of Pharmacy and Pharmacology, 2011, 49, 682-686.	2.4	40

#	Article	IF	Citations
73	FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL. Drug Metabolism and Disposition, 2006, 34, 1182-1189.	3.3	39
74	Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharmaceutical Research, 1993, 10, 727-731.	3.5	38
75	The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CL_{int}), Maximum Velocity of the Metabolic Reaction (V_{max}), and Michaelis Constant (K_m): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations. Drug Metabolism and Disposition, 2009, 37, 47-58.	3.3	38
76	The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. European Journal of Pharmaceutical Sciences, 2009, 36, 433-443.	4.0	38
77	InÂVitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System. Journal of Pharmaceutical Sciences, 2016, 105, 3387-3398.	3.3	37
78	Regional Intestinal Permeability in Rats: A Comparison of Methods. Molecular Pharmaceutics, 2017, 14, 4252-4261.	4.6	37
79	Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000. Pharmaceutical Research, 1993, 10, 130-135.	3.5	36
80	A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. European Journal of Pharmaceutical Sciences, 1999, 8, 19-27.	4.0	36
81	Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-GutÂ®) in humans. European Journal of Pharmaceutical Sciences, 2001, 12, 239-250.	4.0	35
82	Water-soluble Î²-Cyclodextnns in Paediatnc Oral Solutions of Spironolactone: Preclinical Evaluation of Spironolactone Bioavailability from Solutions of Î²-Cyclodextrin Derivatives in Rats. Journal of Pharmacy and Pharmacology, 2011, 50, 611-619.	2.4	34
83	Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker ⁵¹Cr-EDTA. Molecular Pharmaceutics, 2017, 14, 4243-4251.	4.6	34
84	IMI â€“ oral biopharmaceutics tools project â€“ evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds. European Journal of Pharmaceutical Sciences, 2017, 96, 598-609.	4.0	34
85	Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms. Molecular Pharmaceutics, 2016, 13, 3022-3033.	4.6	32
86	Pulmonary absorption â€“ estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, 1-12.	4.3	31
87	Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems. Therapeutic Delivery, 2014, 5, 447-466.	2.2	30
88	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. Molecular Pharmaceutics, 2017, 14, 448-458.	4.6	30
89	Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. Cells, 2022, 11, 632.	4.1	30
90	Gastrointestinal metabolism of a vegetable-oil emulsion in healthy subjects. American Journal of Clinical Nutrition, 2010, 92, 515-524.	4.7	29

#	Article	IF	Citations
91	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. European Journal of Pharmaceutical Sciences, 2022, 170, 106098.	4.0	29
92	Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharmaceutical Research, 1997, 14, 1780-1785.	3.5	28
93	Enterohepatic Disposition of Rosuvastatin in Pigs and the Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil. Drug Metabolism and Disposition, 2009, 37, 2349-2358.	3.3	27
94	Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. Journal of Pharmacy and Pharmacology, 2010, 55, 963-972.	2.4	27
95	Effects of cholesterol and model transmembrane proteins on drug partitioning into lipid bilayers as analysed by immobilized-liposome chromatography. Journal of Pharmacy and Pharmacology, 2010, 53, 1477-1487.	2.4	26
96	Intestinal drug absorption and bioavailability: beyond involvement of single transport function. Journal of Pharmacy and Pharmacology, 2010, 55, 429-433.	2.4	26
97	Concentration- and Region-dependent Intestinal Permeability of Fluvastatin in the Rat. Journal of Pharmacy and Pharmacology, 2011, 50, 737-744.	2.4	25
98	In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma. Cells, 2021, 10, 1717.	4.1	25
99	A new approach for direct in vivo dissolution studies of poorly soluble drugs. Pharmaceutical Research, 1997, 14, 1490-1492.	3.5	24
100	High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery. Peptides, 2002, 23, 469-478.	2.4	24
101	The Pharmacokinetics and Hepatic Disposition of Repaglinide in Pigs: Mechanistic Modeling of Metabolism and Transport. Molecular Pharmaceutics, 2012, 9, 823-841.	4.6	24
102	Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 804, 303-311.	2.3	23
103	Investigation of Hepatobiliary Disposition of Doxorubicin Following Intrahepatic Delivery of Different Dosage Forms. Molecular Pharmaceutics, 2014, 11, 131-144.	4.6	23
104	Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. Drug Metabolism and Disposition, 2018, 46, 1420-1433.	3.3	23
105	Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model. Molecular Pharmaceutics, 2019, 16, 3053-3064.	4.6	23
106	Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 749-758.	3.3	21
107	Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs. European Journal of Pharmaceutical Sciences, 2014, 53, 17-27.	4.0	21
108	A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. Molecular Pharmaceutics, 2017, 14, 686-698.	4.6	21

#	Article	IF	Citations
109	Permeability and clearance views of drug absorption: A commentary. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23, 333-337.	0.6	20
110	Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption. AAPS Journal, 2015, 17, 1177-1192.	4.4	20
111	Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences, 2003, 19, 57-65.	4.0	19
112	Intestinal and Hepatobiliary Transport of Ximelagatran and Its Metabolites in Pigs. Drug Metabolism and Disposition, 2008, 36, 1519-1528.	3.3	19
113	Pharmacokinetics of an Injectable Modified-Release 2-Hydroxyflutamide Formulation in the Human Prostate Gland Using a Semiphysiologically Based Biopharmaceutical Model. Molecular Pharmaceutics, 2014, 11, 3097-3111.	4.6	19
114	Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obesity Science and Practice, 2020, 6, 313-323.	1.9	18
115	Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2009, 37, 2008-2017.	3.3	17
116	Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in Bile and Plasma in Healthy Volunteers. Journal of Clinical Pharmacology, 2010, 50, 1039-1049.	2.0	17
117	Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Molecular Pharmaceutics, 2015, 12, 4166-4173.	4.6	17
118	Different Effects of Ketoconazole on the Stereoselective First-Pass Metabolism of R/S-Verapamil in the Intestine and the Liver: Important for the Mechanistic Understanding of First-Pass Drug-Drug Interactions. Drug Metabolism and Disposition, 2009, 37, 2186-2196.	3.3	16
119	Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 191-202.	4.3	16
120	Drug Absorption Parameters Obtained Using the Isolated Perfused Rat Lung Model Are Predictive of Rat In Vivo Lung Absorption. AAPS Journal, 2020, 22, 71.	4.4	16
121	Is the jejunal permeability in rats age-dependent?. Pharmaceutical Research, 1997, 14, 1278-1281.	3.5	15
122	Regional differences in bioavailability of an opioid tetrapeptide in vivo in rats after administration to the respiratory tract. Peptides, 2002, 23, 479-488.	2.4	15
123	In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5Î±-Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole. Drug Metabolism and Disposition, 2011, 39, 847-857.	3.3	15
124	The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin. Pharmaceutics, 2020, 12, 99.	4.5	15
125	Surface activity and concentration dependent intestinal permeability in the rat. Pharmaceutical Research, 1999, 16, 97-102.	3.5	14
126	Combined in Vitroâ€“in Vivo Approach To Assess the Hepatobiliary Disposition of a Novel Oral Thrombin Inhibitor. Molecular Pharmaceutics, 2013, 10, 4252-4262.	4.6	14

#	Article	IF	Citations
127	Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality. Journal of Drug Delivery Science and Technology, 2019, 53, 101143.	3.0	14
128	Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules, 2020, 25, 2861.	3.8	14
129	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 13051.	4.1	14
130	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Molecular Pharmaceutics, 2020, 17, 361-372.	4.6	13
131	Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat. Pharmaceutics, 2020, 12, 242.	4.5	13
132	Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations. Applied Sciences (Switzerland), 2020, 10, 2376.	2.5	13
133	Intestinal and bloodâ€“brain drug transport: beyond involvement of a single transport function. Drug Discovery Today: Technologies, 2004, 1, 417-422.	4.0	12
134	Extensive intestinal glucuronidation of raloxifenein vivoin pigs and impact for oral drug delivery. Xenobiotica, 2012, 42, 917-928.	1.1	12
135	No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in rats. AAPS PharmSci, 2000, 2, 62-68.	1.3	11
136	Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs. Drug Development and Industrial Pharmacy, 2017, 43, 338-346.	2.0	10
137	Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death. Cells, 2021, 10, 1163.	4.1	10
138	The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs. Molecular Pharmaceutics, 2014, 11, 1301-1313.	4.6	9
139	Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LCâ€“MS/MS) of ximelagatran and its metabolites in a complex matrix. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 291-297.	2.3	7
140	Effects of Ketoconazole on the In Vivo Biotransformation and Hepatobiliary Transport of the Thrombin Inhibitor AZD0837 in Pigs. Drug Metabolism and Disposition, 2011, 39, 239-246.	3.3	7
141	An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. Journal of Urology, 2017, 198, 1333-1339.	0.4	7
142	Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment. AAPS Journal, 2018, 20, 96.	4.4	7
143	Prevention of Rat Intestinal Injury with a Drug Combination of Melatonin and Misoprostol. International Journal of Molecular Sciences, 2020, 21, 6771.	4.1	7
144	Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. Journal of Pharmacy and Pharmacology, 2017, 69, 135-142.	2.4	6

#	Article	IF	Citations
145	Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats. International Journal of Molecular Sciences, 2022, 23, 1021.	4.1	6
146	Binding Processes Determine the Stereoselective Intestinal and Hepatic Extraction of Verapamil in Vivo. Molecular Pharmaceutics, 2012, 9, 3034-3045.	4.6	5
147	Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. European Journal of Pharmaceutical Sciences, 2014, 57, 214-223.	4.0	5
148	Does the choice of applied physiologicallyâ€based pharmacokinetics platform matter? A case study on simvastatin disposition and drugâ€“drug interaction. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1194-1209.	2.5	5
149	Biliary Excretion of Ximelagatran and Its Metabolites and the Influence of Erythromycin Following Intraintestinal Administration to Healthy Volunteers. Journal of Clinical Pharmacology, 2011, 51, 770-783.	2.0	4
150	Melatonin-Activated Receptor Signaling Pathways Mediate Protective Effects on Surfactant-Induced Increase in Jejunal Mucosal Permeability in Rats. International Journal of Molecular Sciences, 2021, 22, 10762.	4.1	4
151	Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. Pharmaceutics, 2022, 14, 801.	4.5	4
152	Hepatic Disposition of Ximelagatran and Its Metabolites in Pig; Prediction of the Impact of Membrane Transporters Through a Simple Disposition Model. Pharmaceutical Research, 2010, 27, 597-607.	3.5	3
153	Oral biopharmaceutics-current status and identified gaps of understanding. European Journal of Pharmaceutical Sciences, 2014, 57, 98.	4.0	3
154	Oral Drug Delivery, Absorption and Bioavailability. , 2022, , 406-437.		3
155	Drug diffusion in biomimetic hydrogels: importance for drug transport and delivery in non-vascular tumor tissue. European Journal of Pharmaceutical Sciences, 2022, 172, 106150.	4.0	3
156	High-resolution mass spectrometric investigation of the phase I and II metabolites of finasteride in pig plasma, urine and bile. Xenobiotica, 2014, 44, 498-510.	1.1	2
157	St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism*1. Clinical Pharmacology and Therapeutics, 2004, 75, 298-309.	4.7	2
158	Protective Effects of Melatonin and Misoprostol against Experimentally Induced Increases in Intestinal Permeability in Rats. International Journal of Molecular Sciences, 2022, 23, 2912.	4.1	2
159	Reply to â€œComment on â€˜In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinomaâ€™â€• Molecular Pharmaceutics, 2018, 15, 336-340.	4.6	1